ABT Stock Recent News
ABT LATEST HEADLINES
Abbott Laboratories said on Tuesday the U.S. FDA has approved its heart valve repair device designed for patients at risk of complications or death during open-heart surgeries.
Abbott (ABT) concluded the recent trading session at $112.09, signifying a -1.38% move from its prior day's close.
As the number of grey-haired people rises worldwide, investors need to notice the strong-buy healthcare stocks. The need for healthcare will grow as the number of people aged 60 years and older doubles by 2050, a situation never before witnessed in the world, thanks to smaller families and longer lifespans.
ABBOTT PARK, Ill., March 27, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2024 financial results on Wednesday, April 17, before the market opens.
Abbott's (ABT) Assert-IQ ICM enables regular monitoring for abnormal heart rhythms, as well as technologies to improve data management and workflow.
In the closing of the recent trading day, Abbott (ABT) stood at $111.50, denoting a +1.35% change from the preceding trading day.
Zacks.com users have recently been watching Abbott Laboratories (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Seasoned investors typically pay close attention to “stocks with analyst approval,” a sign of potential success and resilience in the ever-volatile equity market landscape. Currently, we are in a period of rapid technological advancements in artificial intelligence (AI) and shifting economic paradigms amid expected interest rate cuts.
Abbott's (ABT) Eterna SCS system reduces pain without causing discomfort. It leverages the BurstDR stimulation technology.
Jim Cramer is a highly polarizing figure on the investing scene. Somewhere between a financial expert and a prime-time TV personality, Cramer has built a reputation as a dynamic, boisterous, and controversial advisor to the average American investor.